1,093,789 Shares in IQVIA Holdings Inc. $IQV Bought by Legal & General Group Plc

Legal & General Group Plc acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 1,093,789 shares of the medical research company’s stock, valued at approximately $211,342,000. Legal & General Group Plc owned 0.66% of IQVIA as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new position in IQVIA during the 2nd quarter valued at about $121,523,000. Trajan Wealth LLC bought a new position in shares of IQVIA in the second quarter valued at approximately $35,266,000. Peak Asset Management LLC bought a new stake in IQVIA during the second quarter worth approximately $474,000. L2 Asset Management LLC acquired a new stake in IQVIA in the second quarter worth approximately $1,942,000. Finally, Vega Investment Solutions acquired a new position in shares of IQVIA during the 2nd quarter valued at $709,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Up 0.8%

NYSE:IQV opened at $261.57 on Thursday. The business’s fifty day moving average price is $218.41 and its 200 day moving average price is $188.59. The firm has a market capitalization of $43.05 billion, a price-to-earnings ratio of 32.45, a PEG ratio of 2.22 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $262.51.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the business earned $2.81 EPS. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the sale, the insider owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 in the last 90 days. 1.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IQV. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Stifel Nicolaus upped their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. BMO Capital Markets raised their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Mizuho increased their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.